- Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors
-
The structure-activity relationship studies of a novel series of carboxylic acid derivatives of pyridine-carboxamides as DGAT-1 inhibitors is described. The optimization of the initial lead compound 6 based on in vitro and in vivo activity led to the disc
- Ting, Pauline C.,Lee, Joe F.,Zorn, Nicolas,Kim, Hyunjin M.,Aslanian, Robert G.,Lin, Mingxiang,Smith, Michelle,Walker, Scott S.,Cook, John,Van Heek, Margaret,Lachowicz, Jean
-
p. 985 - 988
(2013/03/13)
-
- INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
-
The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I).
- -
-
-
- INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
-
The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (DGAT) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below:
- -
-
Page/Page column 68-69
(2011/04/18)
-